Aducanumab: What About the Patient?; Risk of Aneurysm Rupture After Stroke Thrombolysis
Neurology® Podcast
00:00
Anti-Amyloid Medication
I think you've, again, touched on some pretty key points with this medication and with its roll out. If we think of agicanymab as a first in class anti ameloid medication. Do you think that this big step forward, as controversial as it's been, is the start of something, something good, something to look forward to? I really do. Greg.
Transcript
Play full episode
